

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4413130

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
JEFFERIES FINANCE LLC		05/11/2017
RECEIVING PARTY DATA		
Name:	AMAG PHARMACEUTICALS, INC.	
Street Address:	1100 WINTER STREET	
City:	WALTHAM	
State/Country:	MASSACHUSETTS	
Postal Code:	02451	
PROPERTY NUMBERS Total: 27		
Property Type	Number	
Patent Number:	6599498	
Patent Number:	7553479	
Patent Number:	7871597	
Patent Number:	8501158	
Patent Number:	8591864	
Patent Number:	8926947	
Patent Number:	5490991	
Patent Number:	5589591	
Patent Number:	5981507	
Patent Number:	5679323	
Patent Number:	5055288	
Patent Number:	4951675	
Patent Number:	5069216	
Patent Number:	5102652	
Patent Number:	5160726	
Patent Number:	5262176	
Patent Number:	5248492	
Patent Number:	5219554	
Patent Number:	5352432	
Patent Number:	5342607	

PATENT

Property Type	Number
Patent Number:	5336506
Patent Number:	5314679
Patent Number:	5554386
Patent Number:	5478576
Application Number:	13937923
Application Number:	13197153
Application Number:	12145565

CORRESPONDENCE DATA

Fax Number: (212)355-3333

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2124597136

Email: tbennett@goodwinlaw.com

Correspondent Name: TRACEY D. BENNETT

Address Line 1: C/O GOODWIN PROCTER LLP

Address Line 2: 620 8TH AVE.

Address Line 4: NEW YORK, NEW YORK 10018

ATTORNEY DOCKET NUMBER:	124885.242580
NAME OF SUBMITTER:	TRACEY D. BENNETT
SIGNATURE:	/s/Tracey D. Bennett
DATE SIGNED:	05/15/2017

Total Attachments: 31

source=AMAG - IP Release (Executed)#page1.tif
source=AMAG - IP Release (Executed)#page2.tif
source=AMAG - IP Release (Executed)#page3.tif
source=AMAG - IP Release (Executed)#page4.tif
source=AMAG - IP Release (Executed)#page5.tif
source=AMAG - IP Release (Executed)#page6.tif
source=AMAG - IP Release (Executed)#page7.tif
source=AMAG - IP Release (Executed)#page8.tif
source=AMAG - IP Release (Executed)#page9.tif
source=AMAG - IP Release (Executed)#page10.tif
source=AMAG - IP Release (Executed)#page11.tif
source=AMAG - IP Release (Executed)#page12.tif
source=AMAG - IP Release (Executed)#page13.tif
source=AMAG - IP Release (Executed)#page14.tif
source=AMAG - IP Release (Executed)#page15.tif
source=AMAG - IP Release (Executed)#page16.tif
source=AMAG - IP Release (Executed)#page17.tif
source=AMAG - IP Release (Executed)#page18.tif
source=AMAG - IP Release (Executed)#page19.tif
source=AMAG - IP Release (Executed)#page20.tif

source=AMAG - IP Release (Executed)#page21.tif
source=AMAG - IP Release (Executed)#page22.tif
source=AMAG - IP Release (Executed)#page23.tif
source=AMAG - IP Release (Executed)#page24.tif
source=AMAG - IP Release (Executed)#page25.tif
source=AMAG - IP Release (Executed)#page26.tif
source=AMAG - IP Release (Executed)#page27.tif
source=AMAG - IP Release (Executed)#page28.tif
source=AMAG - IP Release (Executed)#page29.tif
source=AMAG - IP Release (Executed)#page30.tif
source=AMAG - IP Release (Executed)#page31.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this “Release”) is made as of May 11, 2017 (the “Effective Date”), by JEFFERIES FINANCE LLC, as collateral agent for the Finance Parties (the “Agent”), in favor of the Grantors (as defined below). Capitalized terms used but not otherwise defined herein have the meanings given to them in the applicable Security Agreement (as defined below), applicable IP Security Agreement (as defined below) or Credit Agreement (as defined in the 2015 Security Agreement), as applicable.

WHEREAS, pursuant to (i) that certain Security Agreement dated as of November 12, 2014 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2014 Security Agreement”) among AMAG PHARMACEUTICALS, INC., a Delaware corporation (“AMAG”), LUMARA HEALTH INC., a Delaware corporation (“Lumara”), LUMARA HEALTH IP LTD., a Delaware corporation (“Lumara IP”) and the Agent and (ii) that certain Security Agreement dated as of August 17, 2015 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2015 Security Agreement”; together with the 2014 Security Agreement, each a “Security Agreement” and collectively, the “Security Agreements”) among AMAG, Lumara, Lumara IP, CBR ACQUISITION HOLDINGS CORP., a Delaware corporation (“Acquisition”) and CBR SYSTEMS, INC., a Delaware corporation (“Systems”; and together with AMAG, Lumara, Lumara IP and Acquisition, each a “Grantor” and collectively, the “Grantors”) and the Agent, pursuant to which the Grantors executed and delivered to the Agent (i) that certain Grant of Security Interest in United States Patent and Trademarks and (ii) that certain Grant of Security Interest in United States Copyrights (each an “IP Security Agreement”; and collectively, the “IP Security Agreements”), for recordation with the United States Patent and Trademark Office (the “USPTO”) and the United States Copyright Office (the “USCO”), as applicable;

WHEREAS, the IP Security Agreements were recorded with the USPTO on (i) November 12, 2014 with the trademark assignment division at Reel 5399, Frame 0983 for AMAG and at Reel 5400, Frame 0009 for Lumara IP and (ii) September 25, 2015 at Reel 5630, Frame 0335 for AMAG, at Reel 5630, Frame 0285 for Lumara IP and at Reel 5630, Frame 0314 for Systems;

WHEREAS the IP Security Agreements were recorded with the USPTO on (i) November 12, 2014 with the patent assignment division at Reel 034156, Frame 0214 for AMAG, at Reel 034156, Frame 0243 for Lumina IP, (ii) September 25, 2015 at Reel 036653, Frame 0065 for AMAG and at Reel 036653, Frame 0138 for Lumara IP and (iii) January 29, 2016 at Reel 037623, Frame 0181 for Systems;

WHEREAS the IP Security Agreements were recorded with the USCO on (i) November 14, 2014 at Document Number V9922D109 and (ii) October 28, 2015 at Document Number V9927D501 for Lumara; and

WHEREAS, pursuant to the terms and conditions of the Security Agreements and the IP Security Agreements, each Grantor assigned and pledged to the Agent, for the benefit of the Finance Parties, a security interest in all of each Grantor’s right, title and interest in, to and under the following, whether then presently existing or thereafter arising or acquired (i) all United States trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos, certification marks, collective marks, brand names, trademark rights arising out of domain names and trade dress which are or have been used in the United States, in any state, province or territory or possession thereof, or in any other place, nation or jurisdiction, package and other designs, and any other source or business identifiers, and general intangibles of like nature, and the rights in any of the

foregoing which arise under applicable Law, in each case whether registered or unregistered, and with respect to any and all of the foregoing: (a) the goodwill of the business symbolized thereby or associated therewith; (b) all registrations and applications in connection therewith, including registrations and applications in the USPTO or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, and including, without limitation, the registrations and applications referred to in Schedule A hereto; (c) all extensions and renewals thereof; (d) all claims for, and rights to sue for, past, present or future infringements, dilutions, and other violations thereof; (e) all Proceeds of the foregoing, including, without limitation, all income, license fees, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing, including damages and payments for past, present or future infringements, dilutions, or other violations thereof; and (f) all other rights corresponding thereto throughout the world, (ii) all United States patents and patent applications, including, without limitation the patents and patent applications referred to in Schedule B hereto, and, with respect to any and all of the foregoing: (a) all reissues, reexaminations, divisions, continuations, continuations-in-part, revisions, renewals or extensions thereof; (b) all claims for, and rights to sue for, past, present or future infringements and other violations thereof; (c) all Proceeds of the foregoing, including, without limitation, all income, license fees, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing, including damages and payments for past, present or future infringements or other violations thereof; and (d) all other rights corresponding thereto throughout the world and (iii) (a) all United States copyrights (including community designs), including but not limited to copyrights in software and databases, and all Mask Works (as defined under 17 U.S.C. § 901 of the U.S. Copyright Act), whether registered or unregistered; (b) all registrations and applications therefor including, without limitation, the registrations and applications referred to in Schedule C hereto, and all extensions and renewals thereof; (c) all claims for, and rights to sue for, past, present or future infringements and other violations thereof and (d) all Proceeds of the foregoing, including, without limitation, all income, license fees, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing, including damages and payments for past, present or future infringements or other violations thereof (collectively, the “IP Collateral”).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent, for the benefit of the Finance Parties, hereby agrees as follows:

The Agent hereby terminates the IP Security Agreements, and hereby terminates and releases the security interest in the IP Collateral arising under the Security Agreements and the IP Security Agreements.

If and to the extent the Agent has acquired any right, title or interest in, to or under any of the IP Collateral, it hereby irrevocably reassigns and retransfers all such right, title and interest to each Grantor.

This Release and the rights and obligations of the parties hereunder shall be governed by, and shall be construed and enforced in accordance with, the laws of the State of New York without regard to conflict of laws principles thereto.

[Signature page to follow]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

JEFFERIES FINANCE LLC, as Collateral
Agent

By:

Name:
Title:

A handwritten signature in black ink, appearing to read "J. Paul McDonnell", written over a horizontal line.

J. Paul McDonnell
Managing Director

SCHEDULE A

Trademarks

See attached.

AMAG PHARMACEUTICALS, INC.

TRADEMARKS

<u>Title</u>	<u>Date</u>	<u>Registration No.</u>	<u>Country</u>
A Design	7/19/2011	3,998,406	United States of America
A Design	3/15/2011	3,932,595	United States of America
AMAG PHARMACEUTICALS	4/19/2011	3,949,095	United States of America
AMAG PHARMACEUTICALS	7/26/2011	4,002,635	United States of America
FERAHEME	11/3/2009	3,706,009	United States of America
FERAHEME FERUMOXYTOL INJECTION	4/8/2014	4,509,702	United States of America
FERIDEX I.V.	4/8/1997	2,051,253	United States of America
IRON MATTERS	2/4/2014	4,477,864	United States of America
IRON MATTERS FE	2/11/2014	4,480,662	United States of America
COMBIDEX	8/20/1997	1080152	China (People's Republic)
COMBIDEX	9/8/1997	IDM000067861	Indonesia
COMBIDEX	10/9/1997	4067522	Japan
COMBIDEX	7/15/1997	2,080,060	United States of America
COMBIDEX	3/13/1998	4124269	Japan
FERAHEME	12/12/2011	131637	United Arab Emirates
FERAHEME	8/18/2009	1013917	Armenia
FERAHEME	5/28/2010	2371609	Argentina
FERAHEME	8/18/2009	1325788	Australia
FERAHEME	8/18/2009	1013917	Azerbaijan
FERAHEME	8/18/2009	1013917	Bulgaria
FERAHEME	8/18/2009	1013917	Bahrain
FERAHEME	4/5/2011	830155201	Brazil
FERAHEME	8/18/2009	1013917	Botswana
FERAHEME	1/18/2013	TMA840656	Canada
FERAHEME	5/15/2009	586630	Switzerland
FERAHEME	8/14/2010	71226217	China
FERAHEME	4/17/2011	235202	Egypt
FERAHEME	6/9/2009	7480916	European Union
FERAHEME	8/18/2009	1013917	Georgia
FERAHEME	10/15/2012	1013917	Ghana
FERAHEME	1/21/2010	301409805	Hong Kong
FERAHEME	12/5/2010	223049	Israel
FERAHEME	2/14/2011	1766038	India
FERAHEME	10/15/2012	1013917	International Registration – Madrid Agreement / Protocol
FERAHEME	8/18/2009	1013917	Iran
FERAHEME	12/22/2010	110492	Jordan
FERAHEME	8/18/2009	1013917	Japan
FERAHEME	8/18/2009	1013917	Kenya
FERAHEME	8/18/2009	1013917	Kyrgyz Republic
FERAHEME	8/18/2009	1013917	Korea
FERAHEME	10/3/2011	87321	Kuwait
FERAHEME	10/27/2009	124699	Lebanon
FERAHEME	8/18/2009	1013917	Lesotho
FERAHEME	8/18/2009	1013917	Madagascar
FERAHEME	8/18/2009	1013917	Morocco
FERAHEME	8/18/2009	1013917	Moldova
FERAHEME	2/11/2009	1083624	Mexico
FERAHEME	8/18/2009	1013917	Mozambique

FERAHEME	8/18/2009	1013917	Namibia
FERAHEME	8/18/2009	1013917	Oman
FERAHEME	8/18/2009	1013917	Russia
FERAHEME	10/19/2010	1201/36	Saudi Arabia
FERAHEME	8/18/2009	1013917	Sierra Leona
FERAHEME	8/18/2009	1013917	Syria
FERAHEME	8/18/2009	1013917	Swaziland
FERAHEME	8/18/2009	1013917	Turkmenistan
FERAHEME	8/18/2009	1013917	Turkey
FERAHEME	5/1/2010	1407366	Taiwan
FERAHEME	8/18/2009	1013917	Uzbekistan
FERAHEME	10/23/2010	49234	Yemen
FERAHEME	4/8/2011	2009/15976	South Africa
FERAHEME	8/18/2009	1013917	Zambia
FERIDEX	6/29/1994	2678804	Japan
FERIDEX	8/15/1997	4044105	Japan
FERIDEX I.V.	7/15/1998	808587	Taiwan

TRADEMARK APPLICATIONS

<u>Title</u>	<u>Date</u>	<u>Application No.</u>	<u>Country</u>
A logo	8/12/2013	86/035,599	United States
AMAG 2018 GROWING BUILDING TOGETHER	12/9/2013	86/138,446	United States
AMAG ASSIST (Stylized)	7/23/2015	86/702064	United States
AMAG PHARMACEUTICALS	8/12/2013	86/035,596	United States
FERAHEME	8/15/2013	13078152	China
FERAHEME	8/29/2010	20926	Libya
FERAHEME	9/24/2009	272642	Pakistan
MY ADHERENCE PROGRAM	2/18/2015	86/538701	United States
MY ADHERENCE PROGRAM BY LUMARA HEALTH (Stylized)	2/18/2015	86/538707	United States

TRADEMARKS

<u>Registration No.</u>	<u>Country</u>	<u>Issue Date</u>	<u>Mark</u>
3,998,406	United States of America	7/19/2011	A Design
3,932,595	United States of America	3/15/2011	A Design
3,949,095	United States of America	4/19/2011	AMAG PHARMACEUTICALS
4,002,635	United States of America	7/26/2011	AMAG PHARMACEUTICALS
3,706,009	United States of America	11/3/2009	FERAHEME
4,509,702	United States of America	1/21/2014	FERAHEME FERUMOXYTOL INJECTION
2,051,253	United States of America	4/8/1997	FERIDEX I.V.
4,477,864	United States of America	2/4/2014	IRON MATTERS
4,480,662	United States of America	2/11/2014	IRON MATTERS FE
1,498,200	United States of America	08/02/1998	FERIDEX
2,080,060	United States of America	7/15/1997	COMBIDEX

TRADEMARK APPLICATIONS

<u>Application No.</u>	<u>Country</u>	<u>Application Date</u>	<u>Mark</u>
86/035,599	United States of America	8/12/2013	A logo
86/138,446	United States of America	12/9/2013	AMAG 2018 GROWING BUILDING TOGETHER
86/035,596	United States of America	8/12/2013	AMAG PHARMACEUTICALS
77/159,943	United States of America	04/18/2007	CELESTIA PHARMACEUTICALS

LUMARA HEALTH IP LTD.

TRADEMARKS

<u>Mark</u>	<u>Issued Date</u>	<u>Registration No.</u>	<u>Country</u>
CHROMAGEN	2/17/2006	651775	Korea, Republic of
CHROMAGEN	6/9/1981	1,156,939	United States of America
CHRONOMETRIC SYSTEM	3/11/2008	3,395,236	United States of America
CONTINUUM OF CARE	5/10/2005	2,948,258	United States of America
ENCORA	7/4/2006	3,111,521	United States of America
ENCORA	6/19/2006	P-271446	Venezuela
ENCORA	9/1/2005	862011	Int'l Registration - Madrid Agreement / Protocol
ENCORA	9/1/2005	862011	Croatia
ENCORA	9/1/2005	862011	European Community
ENCORA	9/1/2005	862011	Georgia
ENCORA	9/1/2005	862011	Bulgaria
ENCORA	9/1/2005	862011	Belarus
ENCORA	9/1/2005	862011	Armenia
ENCORA	9/1/2005	1080029	Australia
ENCORA	12/1/2005	110811	Peru
ENCORA	9/1/2005	862011	Norway
ENCORA	9/1/2005	862011	Russian Federation
ENCORA	9/1/2005	862011	Romania
ENCORA	9/1/2005	862011	Netherlands Antilles
ENCORA	9/1/2005	862011	Macedonia
ENCORA	9/1/2005	862011	Morocco
ENCORA	9/1/2005	862011	Moldova
ENCORA	9/1/2005	862011	Korea, Republic of
ENCORA	9/1/2005	862011	Turkey
ENCORA	9/1/2005	862011	Switzerland
ENCORA	9/1/2005	862011	Singapore
ENCORA	9/1/2005	862011	Turkmenistan
ENCORA	9/1/2005	862011	Ukraine
HISTA-VENT	1/14/1997	2,031,080	United States of America
NATALCARE	1/14/1997	2,031,082	United States of America
NIFEREX	5/10/1977	805414	Chile
NIFEREX	9/3/1982	TMA272454	Canada
NIFEREX	5/8/2008	2230474	Argentina
NIFEREX	10/1/1975	335021	Benelux
NIFEREX	12/30/1969	76093	Ireland
NIFEREX	2/1/1968	29327	Taiwan
NIFEREX	3/1/1966	0,804,556	United States of America
NIFEREX	1/2/1970	953144	United Kingdom
NIFEREX	7/15/1987	P-356222	Switzerland
NIFEREX	7/30/1975	75/4026	South Africa
NIFEREX	2/17/2006	651774	Korea, Republic of
NIFEREX	9/15/2005	108924	Peru
NIFEREX GOLD	9/11/2007	3,291,637	United States of America
OMEGANATE	4/12/2005	2,940,425	United States of America
PRE CARE CONCEIVE	5/27/2003	2,719,613	United States of America

PRECARE	11/3/2004	40-598104	Korea, Republic of
PRECARE	3/21/2003	TMA577898	Canada
PRECARE	6/28/2007	4169901	China (People's Republic)
PRECARE	10/15/1985	1,365,182	United States of America
PRECARE PREMIER	10/23/2007	3,320,970	United States of America
PREMESISRX	11/29/2004	40-0601006	Korea, Republic of
PREMESISRX	11/3/2004	40-598103	Korea, Republic of
PREMESISRX	5/21/2007	4169903	China (People's Republic)
PRIMACARE	11/3/2004	40-598102	Korea, Republic of
PRIMACARE	6/18/2002	2,582,817	United States of America
PRIMACARE ADVANTAGE	6/23/2009	3,643,470	United States of America
PRIMACARE ONE	4/22/2008	3,414,475	United States of America
PRIMACARE ONE	2/17/2006	651776	Korea, Republic of
PRIMACARE ONE	6/17/2008	1045652	Mexico
PRIMACARE ONE	7/7/2010	6453498	China (People's Republic)
PRIMACARE ONE	1/1/2008	1637065	India
REPLIVA	1/4/2007	183181	Israel
REPLIVA	8/22/2005	862020	Japan
REPLIVA	2/22/2005	81324	Jordan
REPLIVA	8/22/2005	862020	Int'l Registration - Madrid
			Agreement / Protocol
REPLIVA	8/22/2005	1378846	India
REPLIVA	7/16/2007	IDM000128212	Indonesia
REPLIVA	4/26/2007	189306	Hungary
REPLIVA	4/23/2007	4584991	European Community
REPLIVA	8/22/2005	862020	European Community
REPLIVA	6/1/2006	142759	Guatemala
REPLIVA	6/22/2010	112913	Honduras
REPLIVA	6/5/2006	159136	Costa Rica
REPLIVA	8/22/2005	862020	Croatia
REPLIVA	11/29/2005	151081	Dominican Republic
REPLIVA	4/27/2006	2264	Ecuador
REPLIVA	7/4/2006	221B65	El Salvador
REPLIVA	8/22/2005	862020	China (People's Republic)
REPLIVA	3/17/2009	TMA736,418	Canada
REPLIVA	1/24/2006	747649	Chile
REPLIVA	11/21/2005	22735/05	Cambodia
REPLIVA	12/4/2006	106822-C	Bolivia
REPLIVA	8/22/2005	862020	Belarus
REPLIVA	8/22/2005	45257	Bahrain
REPLIVA	8/10/2007	2174409	Argentina
REPLIVA	8/22/2005	862020	Armenia
REPLIVA	8/22/2005	862020	Australia
REPLIVA	11/28/2005	910569	Mexico
REPLIVA	4/5/2006	43935	Malta
REPLIVA	2/22/2005	2005/13807	Malaysia
REPLIVA	8/22/2005	862020	Moldova
REPLIVA	8/27/2005	59506	Kuwait
REPLIVA	8/18/2005	103439	Lebanon
REPLIVA	8/22/2005	862020	Macedonia
REPLIVA	12/22/2006	295821	Paraguay
REPLIVA	7/26/2008	212638	Pakistan
REPLIVA	7/26/2007	144356	Panama
REPLIVA	6/12/2007	0701404LM	Nicaragua
REPLIVA	7/5/2006	37303	Oman
REPLIVA	8/22/2005	862020	Norway

REPLIVA	1/23/2007	889/77	Saudi Arabia
REPLIVA	8/22/2005	862020	Russian Federation
REPLIVA	5/18/2008	36727	Qatar
REPLIVA	4/1/2008	3,406,639	United States of America
REPLIVA	2/6/2007	79512	United Arab Emirates
REPLIVA	8/22/2005	862020	Ukraine
REPLIVA	7/31/2009	2005/16696	South Africa
REPLIVA	8/22/2005	862020	Singapore
REPLIVA	8/22/2005	862020	Switzerland
REPLIVA	7/1/2006	1215983	Taiwan
REPLIVA	8/18/2005	245118	Thailand
REPLIVA	8/22/2005	862020	Turkey
REPLIVA	4/23/2008	364826	Uruguay
REPLIVA	6/19/2006	P271407	Venezuela
REPLIVA	5/21/2007	82254	Vietnam
STRONGSTART	7/29/2003	2,742,749	United States of America
HISTINEX	10/31/1995	1,932,221	United States
KV	4/17/2009	2497357	United Kingdom
KV	4/24/2009	2497365	United Kingdom
KV	10/22/2013	4,422,135	United States
KV PHARMACEUTICAL	10/29/2013	4,425,783	United States
KV PHARMACEUTICAL	4/17/2009	2497358	United Kingdom
KV PHARMACEUTICAL	4/17/2009	2497367	United Kingdom
KV PHARMACEUTICAL & design	4/9/2013	4,317,346	United States
KV PHARMACEUTICAL & design	4/17/2009	2497478	United Kingdom
KV PHARMACEUTICAL & design	4/17/2009	2497361	United Kingdom
MAKENA	5/30/2011	1081707	Singapore
MAKENA	11/9/2012	2011/12410	South Africa
MAKENA	5/30/2011	1081707	Switzerland
MAKENA	11/28/2011	842787	New Zealand
MAKENA	10/6/2011	180385	Peru
MAKENA	5/30/2011	1081707	Russian Federation
MAKENA	5/30/2011	1081707	Korea, Republic of
MAKENA	5/30/2011	1081707	Int'l Registration - Madrid Agreement / Protocol
MAKENA	5/6/2013	2151283	India
MAKENA	5/30/2011	1081707	Israel
MAKENA	5/30/2011	1081707	Japan
MAKENA	5/30/2011	1081707	European Community
MAKENA	5/30/2011	1081707	China
MAKENA	12/16/2011	1436276	Australia
MAKENA	3/27/2013	2561294	Argentina
MAKENA	3/2/2012	945204	Chile
MAKENA	10/24/2012	TMA834990	Canada
MAKENA	10/25/2011	4,046,878	United States
MAKENA CARE CONNECTION	5/29/2012	4,151,045	United States
MAKENA CARES FOUNDATION	8/14/2012	4,191,401	United States
METER RELEASE	9/11/1984	1,293,848	United States
MICRO RELEASE	12/5/1995	1,939,204	United States
MICRO-KC1	7/18/1980	TMA248173	Canada
Mom + Baby (Makena) Logo	10/18/2011	4,042,500	United States

THER-RX	12/4/2012	4,254,188	United States
EVERY WEEK COUNTS	10/04/2011	4,035,424	United States
GUAIFENEX	08/15/1995	1,912,198	United States
FLAVORTECH	08/27/1996	1,997,221	United States

TRADEMARK APPLICATIONS

<u>Mark</u>	<u>Application Date</u>	<u>Application No.</u>	<u>Country</u>
LUMARA	3/4/2014	86/210,647	United States
LUMARA	11/4/2013	86/109,620	United States
Lumara Flower Petals Logo	3/4/2014	86/210,681	United States
MAKENA	7/26/2012	P318837	Venezuela
LUMARA HEALTH	3/12/2015	86/561682	United States
PREMESISRX	6/28/2013	85/972,547	United States of America
REPLIVA	8/19/2005	827755058	Brazil

TRADEMARKS

<u>Registration No.</u>	<u>Country</u>	<u>Issue Date</u>	<u>Mark</u>
1,156,939	United States of America	6/9/1981	CHROMAGEN
3,395,236	United States of America	3/11/2008	CHRONOMETRIC SYSTEM
2,948,258	United States of America	5/10/2005	CONTINUUM OF CARE
3,111,521	United States of America	7/4/2006	ENCORA
2,031,080	United States of America	1/14/1997	HISTA-VENT
2,031,082	United States of America	1/14/1997	NATALCARE
0,804,556	United States of America	3/1/1966	NIFEREX
3,291,637	United States of America	9/11/2007	NIFEREX GOLD
2,940,425	United States of America	4/12/2005	OMEGANATE
2,719,613	United States of America	5/27/2003	PRE CARE CONCEIVE
1,365,182	United States of America	10/15/1985	PRECARE
3,320,970	United States of America	10/23/2007	PRECARE PREMIER
2,582,817	United States of America	6/18/2002	PRIMACARE
3,643,470	United States of America	6/23/2009	PRIMACARE ADVANTAGE
3,414,475	United States of America	4/22/2008	PRIMACARE ONE
3,406,639	United States of America	4/1/2008	REPLIVA
2,742,749	United States of America	7/29/2003	STRONGSTART
1,932,221	United States of America	10/31/1995	HISTINEX
4,422,135	United States of America	10/22/2013	KV
4,425,783	United States of America	10/29/2013	KV PHARMACEUTICALS
4,317,346	United States of America	4/9/2013	KV PHARMACEUTICAL & design
4,046,878	United States of America	10/25/2011	MAKENA
4,151,045	United States of America	5/29/2012	MAKENA CARE
			CONNECTION
4,191,401	United States of America	8/14/2012	MAKENA CARES
			FOUNDATION
1,293,848	United States of America	9/11/1984	METER RELEASE
1,939,204	United States of America	12/5/1995	MICRO RELEASE
4,042,500	United States of America	10/18/2011	Mom + Baby (Makena) Logo
4,254,188	United States of America	12/4/2012	THER-RX
3,184,560	United States of America	12/12/2006	CLINDESSE
4,035,424	United States of America	10/04/2011	EVERY WEEK COUNTS
3,688,522	United States of America	09/29/2009	EVAMIST
3,550,530	United States of America	12/23/2008	EVAMIST
2,457,708	United States of America	06/05/2001	GYNAZOLE 1
1,912,198	United States of America	08/15/1995	GUAIFENEX
1,997,221	United States of America	08/27/1996	FLAVORTECH
3,389,789	United States of America	02/26/2008	REPLIVA 21/7

TRADEMARK APPLICATIONS

<u>Application No.</u>	<u>Country</u>	<u>Application Date</u>	<u>Mark</u>
86/210,647	United States of America	3/4/2014	LUMARA
86/109,620	United States of America	11/4/2013	LUMARA
86/210,681	United States of America	3/4/2014	Lumara Flower Petals Logo
85/972,547	United States of America	6/28/2013	PREMESISRX
86/109,635	United States of America	11/4/2013	ZINNIA
86/210,693	United States of America	3/4/2014	ZINNIA

CBR SYSTEMS, INC.

TRADEMARKS

<u>Mark.</u>	<u>Issue Date</u>	<u>Registration No.</u>	<u>Country</u>
ACTIVEFLO	10/19/2010	3863166	United States
BANK WITH THE BEST	5/14/2013	4333489	United States
CBR	10/11/2006	TMA674547	Canada
CBR	8/28/2008	4475563	China
CBR	7/14/2006	004250916	European Union
CBR	6/9/2005	300358399	Hong Kong
CBR	5/12/2006	4952000	Japan
CBR	7/29/2005	893777	Mexico
CBR	7/28/2005	724298	New Zealand
CBR	1/21/2005	532407	Switzerland
CBR	3/1/2006	1199302	Taiwan R.O.C.
CBR	1/31/2006	3053556	United States
CBR CORD BLOOD REGISTRY (Stylized)	12/8/1998	2207827	United States
CBR SYSTEMS, INC.	3/26/2002	2553256	United States
CELLADVANTAGE	10/30/2007	3323230	United States
CELLADVANTAGE	5/1/2012	4135031	United States
CONNECTING THE EXPECTING	3/16/2010	3761068	United States
CORD BLOOD EDUCATION CENTER	8/31/2010	3843342	United States
CORD BLOOD PARENTS	6/22/2010	3808713	United States
CORD BLOOD REGISTRY	7/27/2010	TMA772988	Canada
CORD BLOOD REGISTRY	8/28/2008	4475562	China
CORD BLOOD REGISTRY	8/28/2008	4475561	China
CORD BLOOD REGISTRY	7/14/2006	004250924	European Union
CORD BLOOD REGISTRY	5/12/2006	4952001	Japan
CORD BLOOD REGISTRY	3/13/2012	1273310	Mexico
CORD BLOOD REGISTRY	2/9/2011	1200223	Mexico
		3065179	United States
CORD BLOOD REGISTRY	3/7/2006		
CORDBANKINGBASICS	8/14/2012	4190174	United States
CORDCUP	8/3/2010	3829843	United States
CORDPREP	2/1/2011	3915134	United States
DESIGNATED TREATMENT PROGRAM	7/6/2010	3813750	United States
DTP	1/4/2011	3898708	United States
		3293807	
FOR YOUR MOST IMPORTANT FORTY WEEKS	9/18/2007		United States
GET MORE FROM THE CORD	2/1/2011	3915133	United States
HEALTHY FUTURES BORN HERE	10/16/2012	4227296	United States
MATERNITY & STYLE (STANDARD CHARACTER MARK)	10/2/2007	3302130	United States

NEWBORN POSSIBILITIES PROGRAM	7/22/2008	3473931	United States
OPEN THE DOORS TO MAXIMUM CELL RECOVERY	2/1/2011	3915147	United States
BABYWEEKLY	3/31/2009	3597687	United States
PREGNANCYWEEKLY	12/15/2009	3724322	United States
SMART SCIENCE. HEALTHY FAMILIES	10/16/2012	4227297	United States
SOFTLOCK	12/7/2010	3886315	United States
THE NAME TO TRUST	6/27/2006	3109023	United States

TRADEMARK APPLICATIONS

<u>Mark</u>	<u>Filing Date</u>	<u>Serial No.</u>	<u>Country</u>
CBR	4/22/2015	2015-1221	Dominican Republic
CBR	5/26/2015	1613896	Mexico
CBR CORD BLOOD REGISTRY (Stylized)	6/11/2015	86/659399	United States
CORD BLOOD REGISTRY	10/21/2014	1255365(1)	Canada
CORD BLOOD REGISTRY	4/22/2015	2015-12210	Dominican Republic
CORDS FOR CURES	5/16/2013	85/934373	United States
CORDS4CURES	5/16/2013	85/934397	United States
JUST BANK IT	11/18/2014	1703246	Canada
JUST BANK IT	11/21/2014	1551190	Mexico
JUST BANK IT	5/22/2014	86/289048	United States
LIVING PROOF	10/31/2013	86/107148	United States
LUSTRE	6/9/2015	86/656,694	United States
NEWBORN POSSIBILITIES (Stylized)	6/22/2015	86/670021	United States
NEWBORN POSSIBILITIES PROGRAM	6/9/2015	86/656,710	United States
PROVING THE POWER OF STEM CELLS	10/31/2013	86/107161	United States
RePAIR: Registry of Pre And post (cord blood) Infusion Results	11/19/2013	86/122586	United States

SCHEDULE B

Patents

See attached.

AMAG PHARMACEUTICALS, INC.

PATENTS AND PATENT APPLICATIONS

<u>Patent Holder</u>	<u>Issue Title</u>	<u>Date</u>	<u>Status</u>	<u>Serial No. or Patent No.</u>	<u>Country</u>
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Austria
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Belgium
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Cyprus, Republic of
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Denmark
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Finland
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	France
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Germany
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Greece
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Ireland
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Italy
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	8/17/2012	Granted	1169062	Japan
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Liechtenstein
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Luxembourg
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Monaco
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Netherlands
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Portugal
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Spain
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Sweden
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	Switzerland
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	10/21/2009	Granted	1169062	United Kingdom
AMAG Pharmaceuticals, Inc.	HEAT STABLE COLLOIDAL IRON OXIDES COATED WITH REDUCED CARBOHYDRATES AND CARBOHYDRATES DERIVATIVES	7/29/2003	Granted	6599498	United States of America
AMAG Pharmaceuticals, Inc.	HEAT STABLE COLLOIDAL IRON OXIDES COATED WITH REDUCED CARBOHYDRATES AND USES THEREOF	6/30/2009	Granted	7553479	United States of America
AMAG	POLYOL AND POLYETHER	1/18/2011	Granted	7871597	United States of

Pharmaceuticals, Inc.	IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS				America
AMAG Pharmaceuticals, Inc.	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	8/6/2013	Granted	8501158	United States of America
AMAG Pharmaceuticals, Inc.	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	11/26/2013	Granted	8591864	United States of America
AMAG Pharmaceuticals, Inc.	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	1/6/2015	Granted	8926947	United States of America
AMAG Pharmaceuticals, Inc.	SYNTHESIS OF POLYACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS	7/17/2002	Granted	0713602	European Patent Convention
AMAG Pharmaceuticals, Inc.	SYNTHESIS OF POLYACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS	7/17/2002	Granted	0713602	France
AMAG Pharmaceuticals, Inc.	SYNTHESIS OF POLYACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS	7/17/2002	Granted	0713602	Germany
AMAG Pharmaceuticals, Inc.	SYNTHESIS OF POLYACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS	7/17/2002	Granted	0713602	Italy
AMAG Pharmaceuticals, Inc.	SYNTHESIS OF POLYACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS	7/17/2002	Granted	0713602	United Kingdom
AMAG Pharmaceuticals, Inc.	DIRECTED DELIVERY OF RADIOPROTECTANTS USING A RECEPTOR SPECIFIC CARRIER	2/13/1996	Granted	5490991	United States of America
AMAG Pharmaceuticals, Inc.	ENDOTOXIN-FREE POLYSACCHARIDES	12/31/1996	Granted	5589591	United States of America
AMAG Pharmaceuticals, Inc.	POLYMERIC CARRIERS LINKED TO NUCLEOTIDE ANALOGUES VIA A PHOPHORMIDE BOND	11/9/1999	Granted	5981507	United States of America
AMAG Pharmaceuticals, Inc.	HEPATOCYTE-SPECIFIC RECEPTOR MEDIATED ENDOCYTOSIS-TYPE COMPOSITIONS CONTRAST AGENTS	10/21/1997	Granted	5679323	United States of America
AMAG Pharmaceuticals, Inc.	VASCULAR MAGNETIC IMAGING METHOD AND AGENT COMPRISING BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES	10/08/1991	Granted	5055288	United States of America
AMAG Pharmaceuticals, Inc.	BIODEGRADABLE SUPERPARAMAGNETIC METAL	08/28/1990	Granted	4951675	United States of America

AMAG Pharmaceuticals, Inc.	OXIDES AS CONTRAST AGENTS FOR MR IMAGING SILANIZED BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR IMAGING THE GASTROINTESTINAL TRACT	12/03/1991	Granted	5069216	United States of America
AMAG Pharmaceuticals, Inc.	LOW MOLECULAR WEIGHT CARBOHYDRATES AS ADDITIVES TO STABILIZE METAL OXIDE COMPOSITIONS	04/07/1992	Granted	5102652	United States of America
AMAG Pharmaceuticals, Inc.	FILTER STERILIZATION FOR PRODUCTION OF COLLOIDAL, SUPERPARAMAGNETIC MR CONTRAST AGENTS	11/03/1992	Granted	5160726	United States of America
AMAG Pharmaceuticals, Inc.	SYNTHESIS OF POLYSACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS	11/16/1993	Granted	5262176	United States of America
AMAG Pharmaceuticals, Inc.	LOW MOLECULAR WEIGHT CARBOHYDRATES AS ADDITIVES TO STABILIZE METAL OXIDE COMPOSITIONS	09/28/1993	Granted	5248492	United States of America
AMAG Pharmaceuticals, Inc.	HYDRATED BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES	06/15/1993	Granted	5219554	United States of America
AMAG Pharmaceuticals, Inc.	ASIALOGLYCOPROTEIN RECEPTOR SPECIFIC COMPOSTIONS AND THEIR USE AS MRI CONTRAST	10/04/1994	Granted	5352432	United States of America
AMAG Pharmaceuticals, Inc.	RECEPTOR MEDIATED ENDOCYTOSIS TYPE MAGNETIC RESONANCE IMAGING CONTRAST AGENTS	08/30/1994	Granted	5342607	United States of America
AMAG Pharmaceuticals, Inc.	TARGETING OF THERAPEUTIC AGENTS USING POLYSACCHARIDES	08/09/1994	Granted	5336506	United States of America
AMAG Pharmaceuticals, Inc.	VASCULAR MAGNETIC RESONANCE IMAGING METHOD COMPRISING NANOPARTICLES	05/24/1994	Granted	5314679	United States of America
AMAG Pharmaceuticals, Inc.	DELIVERY OF THERAPEUTIC AGENTS TO RECEPTORS USING POLYSACCHARIDES	09/10/1996	Granted	5554386	United States of America
AMAG Pharmaceuticals, Inc.	ARABINO GALACTAN DERIVATIVES AND USES THEREOF	12/26/1995	Granted	5478576	United States of America
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	3/8/2000	Opposed	00914867.7	European Patent Convention
AMAG Pharmaceuticals, Inc.	HEAT STABLE COATED COLLOIDAL IRON OXIDES	3/8/2000	Pending	04078335.9	European Patent Convention
AMAG Pharmaceuticals, Inc.	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	7/9/2013	Non-final Action Mailed	13/937923	United States of America

AMAG Pharmaceuticals, Inc.	MACROPHAGE-ENHANCED MRI (MEMRI) IN A SINGLE IMAGING SESSION	8/3/2011	Published	13/197153	United States of America
AMAG Pharmaceuticals, Inc.	MACROPHAGE-ENHANCED MRI (MEMRI)	06/25/2008	Published	12/145565	United States of America

PATENTS AND PATENT APPLICATIONS

<u>Serial No. or Patent No.</u>	<u>Date</u>	<u>Issue Title</u>	<u>Status</u>	<u>Country</u>	<u>Patent Holder</u>
6599498	7/29/2003	HEAT STABLE COLLOIDAL IRON OXIDES COATED WITH REDUCED CARBOHYDRATES AND CARBOHYDRATES DERIVATIVES	Granted	United States of America	AMAG Pharmaceuticals, Inc.
7553479	6/30/2009	HEAT STABLE COLLOIDAL IRON OXIDES COATED WITH REDUCED CARBOHYDRATES AND USES THEREOF	Granted	United States of America	AMAG Pharmaceuticals, Inc.
7871597	1/18/2011	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
8501158	8/6/2013	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
8591864	11/26/2013	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5490991	2/13/1996	DIRECTED DELIVERY OF RADIOPROTECTANTS USING A RECEPTOR SPECIFIC CARRIER	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5589591	12/31/1996	ENDOTOXIN-FREE POLYSACCHARIDES	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5981507	11/9/1999	POLYMERIC CARRIERS LINKED TO NUCLEOTIDE ANALOGUES VIA A PHOSPHORIMIDE BOND	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5679323	10/21/1997	HEPATOCYTE-SPECIFIC RECEPTOR MEDIATED ENDOCYTOSIS-TYPE	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5055288	10/08/1991	VASCULAR MAGNETIC IMAGING METHOD AND AGENT COMPRISING BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES	Granted	United States of America	AMAG Pharmaceuticals, Inc.
4951675	08/28/1990	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR	Granted	United States of America	AMAG Pharmaceuticals, Inc.

5069216	12/03/1991	MR IMAGING SILANIZED BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR IMAGING THE GASTROINTESTINAL TRACT	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5102652	04/07/1992	LOW MOLECULAR WEIGHT CARBOHYDRATES AS ADDITIVES TO STABILIZE METAL OXIDE COMPOSITIONS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5160726	11/03/1993	FILTER STERILIZATION FOR PRODUCTION OF COLLOIDAL, SUPERPARAMAGNETIC MR CONTRAST AGENTS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5262176	11/16/1993	SYNTHESIS OF POLYSACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5248492	09/28/1993	LOW MOLECULAR WEIGHT CARBOHYDRATES AS ADDITIVES TOS TABILIZE METAL OXIDE COMPOSITIONS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5219554	06/15/1993	HYDRATED BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5352432	10/04/1994	ASIALOGLYCOPROTEIN RECEPTOR SPECIFIC COMPOSTIONS AND THEIR USE AS MRI CONTRAST	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5342607	08/30/1994	RECEPTOR MEDIATED ENDOCYTOSIS TYPE MAGNETIC RESONANCE IMAGING CONTRAST AGENTS	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5336506	08/09/1994	TARGETING OF THERAPEUTIC AGENTS USING POLYSACCHARIDES	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5314679	05/24/1994	VASCULAR MAGNETIC RESONANCE IMAGING METHOD COMPRISING NANOPARTICLES	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5554386	09/10/1996	DELIVERY OF THERAPEUTIC AGENTS TO RECEPTORS USING POLYSACCHARIDES	Granted	United States of America	AMAG Pharmaceuticals, Inc.
5478576	12/26/1995	ARABINO GALACTAN DERIVATIVES AND USES THEREOF	Granted	United States of America	AMAG Pharmaceuticals, Inc.

13/937923	7/9/2013	POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS	Pending	United States of America	AMAG Pharmaceuticals, Inc.
13/197153	8/3/2011	MACROPHAGE-ENHANCED MRI (MEMRI) IN A SINGLE IMAGING SESSION	Published	United States of America	AMAG Pharmaceuticals, Inc.
12/145565	06/25/2008	MACROPHAGE-ENHANCED MRI (MEMRI)	Published	United States of America	AMAG Pharmaceuticals, Inc.

LUMARA HEALTH IP LTD.

PATENTS AND PATENT APPLICATIONS

<u>Patent Holder</u>	<u>Issue Title</u>	<u>Date</u>	<u>Status</u>	<u>Serial No or Patent No.</u>	<u>Country</u>
Lumara Health IP Ltd.	MINERAL SUPPLEMENT	9/21/2004	Issued	6793935	United States of America
Lumara Health IP Ltd.	NUTRITIONAL SUPPLEMENTS	7/10/2001	Issued	6258846	United States of America
Lumara Health IP Ltd.	NUTRITIONAL SUPPLEMENTS	6/10/2003	Issued	6576666	United States of America
Lumara Health IP Ltd.	NUTRITIONAL SUPPLEMENTS	9/26/2006	Issued	7112609	United States of America
Lumara Health IP Ltd.	STRIP PACK	4/23/2002	Issued	6375956	United States of America
Lumara Health IP Ltd.	ANTI-NAUSEA COMPOSITIONS AND METHODS	3/6/2001	Issued	6197329	United States of America
Lumara Health IP Ltd.	MAXIMIZING EFFECTIVENESS OF SUBSTANCES USED TO IMPROVE HEALTH AND WELL BEING	8/31/1999	Issued	5945123	United States of America
Lumara Health IP Ltd.	MAXIMIZING EFFECTIVENESS OF SUBSTANCES USED TO IMPROVE HEALTH AND WELL BEING	4/10/2001	Issued	6214379	United States of America
Lumara Health IP Ltd.	RAPIDLY DISINTEGRABLE TABLETS	10/16/2007	Issued	7282217	United States of America
Lumara Health IP Ltd.	DIETARY SUPPLEMENT	5/27/2003	Issued	6569857	United States of America
Lumara Health IP Ltd.	RAPIDLY DISINTEGRABLE TABLETS	9/16/2008	Issued	7425341	United States of America
Lumara Health IP Ltd.	COMPOSITION WITH SUSTAINED RELEASE OF LEVODOPA AND CARBIDOPA	3/11/2003	Issued	6531153	United States of America
Lumara Health IP Ltd.	FOLIC ACID SUPPLEMENT	7/17/2001	Issued	6261600	United States of America
Lumara Health IP Ltd.	FORMULATION FOR MENOPAUSAL WOMEN	11/12/2002	Issued	6479545	United States of America
Lumara Health IP Ltd.	FORMULATION FOR MENOPAUSAL WOMEN	3/30/2010	Issued	7687485	United States of America
Lumara Health IP Ltd.	MULTI-VITAMIN AND MINERAL SUPPLEMENTS FOR WOMEN	2/9/1999	Issued	5869084	United States of America
Lumara Health IP Ltd.	NUTRITIONAL COMPOSITION	3/5/2002	Issued	6352713	United States of America
Lumara Health IP Ltd.	VITAMIN/NUTRIENT DOSAGE REGIMENTATION	2/24/2004	Issued	6696083	United States of America
Lumara Health IP Ltd.	LONG ACTING GI AND ESOPHAGEAL PROTECTANT	09/10/1996	Granted	5554379	United States of America
Lumara Health IP Ltd.	MULTI-VITAMIN AND MINERAL SUPPLEMENT FOR	02/27/1996	Granted	5494678	United States of America

Lumara Health IP Ltd.	PREGNANT WOMEN LONG ACTING GI AND ESOPHAGEAL PROTECTANT	09/23/1997	Granted	5670163	United States of America
Lumara Health IP Ltd.	BIOADHESIVE PHARMACEUTICAL DELIVERY SYSTEM	09/10/1996	Granted	5554380	United States of America
Lumara Health IP Ltd.	LONG ACTING GI AND ESOPHAGEAL PROTECTANT	01/12/1999	Granted	5858391	United States of America
Lumara Health IP Ltd.	MULTI-VITAMIN AND MINERAL SUPPLEMENTS FOR WOMEN	12/03/2002	Granted	6488956	United States of America
Lumara Health IP Ltd.	BIOADHESIVE DRUG DELIVERY SYSTEM	05/31/2005	Granted	6899890	United States of America
Lumara Health IP Ltd.	DELIVERY SYSTEM	11/15/2011	Granted	8057433	United States of America
Lumara Health IP Ltd.	METHODS FOR DETERMINING ABSORPTION OF COBALAMIN OR ANALOGUES THEREOF	06/01/2010	Granted	7727972	United States of America
Lumara Health IP Ltd.	METHODS FOR REDUCING THE OCCURRENCE OF PRETERM DELIVERY AND OTHER PREGNANCY-RELATED CONDITIONS	12/17/2010	Pending	12/971,900	United States of America
Lumara Health IP Ltd.	METHODS OF ADMINISTERING COMPOSITIONS INCLUDING IRON	9/27/2010	Published	12/891,376	United States of America
Lumara Health IP Ltd.	TRANSDERMAL, ALCOHOL-FREE, PHARMACEUTICAL COMPOSITIONS	09/12/2008	Published	12/209864	United States of America
Lumara Health IP Ltd.	PHARMACEUTICAL DELIVERY SYSTEM	07/23/2012	On Appeal	13/555472	United States of America
Lumara Health IP Ltd.	COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS	07/25/2012	Published	13/557527	United States of America
Lumara Health IP Ltd.	ENDOMETRIOSIS TREATMENT	01/03/2013	Published	13/733213	United States of America

PATENTS AND PATENT APPLICATIONS

<u>Serial No. or Patent No.</u>	<u>Date</u>	<u>Issue Title</u>	<u>Status</u>	<u>Country</u>	<u>Patent Holder</u>
6793935	9/21/2004	MINERAL SUPPLEMENT	Issued	United States of America	Lumara Health IP Ltd.
6258846	7/10/2001	NUTRITIONAL SUPPLEMENTS	Issued	United States of America	Lumara Health IP Ltd.
6576666	6/10/2003	NUTRITIONAL SUPPLEMENTS	Issued	United States of America	Lumara Health IP Ltd.
7112609	9/26/2006	NUTRITIONAL SUPPLEMENTS	Issued	United States of America	Lumara Health IP Ltd.
6375956	4/23/2002	STRIP PACK	Issued	United States of America	Lumara Health IP Ltd.
6197329	3/6/2001	ANTI-NAUSEA COMPOSITIONS AND METHODS	Issued	United States of America	Lumara Health IP Ltd.
5945123	8/31/1999	MAXIMIZING EFFECTIVENESS OF SUBSTANCES USED TO IMPROVE HEALTH AND WELL BEING	Issued	United States of America	Lumara Health IP Ltd.
6214379	4/10/2001	MAXIMIZING EFFECTIVENESS OF SUBSTANCES USED TO IMPROVE HEALTH AND WELL BEING	Issued	United States of America	Lumara Health IP Ltd.
7282217	10/16/2007	RAPIDLY DISINTEGRABLE TABLETS	Issued	United States of America	Lumara Health IP Ltd.
6569857	5/27/2003	DIETARY SUPPLEMENT	Issued	United States of America	Lumara Health IP Ltd.
7425341	9/16/2008	RAPIDLY DISINTEGRABLE TABLETS	Issued	United States of America	Lumara Health IP Ltd.
6531153	3/11/2003	COMPOSITION WITH SUSTAINED RELEASE OF LEVODOPA AND CARBIDOPA	Issued	United States of America	Lumara Health IP Ltd.
6261600	7/17/2001	FOLIC ACID SUPPLEMENT	Issued	United States of America	Lumara Health IP Ltd.
6479545	11/12/2002	FORMULATION FOR MENOPAUSAL WOMEN	Issued	United States of America	Lumara Health IP Ltd.
7687485	3/30/2010	FORMULATION FOR MENOPAUSAL WOMEN	Issued	United States of America	Lumara Health IP Ltd.
5869084	2/9/1999	MULTI-VITAMIN AND MINERAL SUPPLEMENTS FOR	Issued	United States of America	Lumara Health IP Ltd.

6352713	3/5/2002	WOMEN NUTRITIONAL COMPOSITION	Issued	United States of America	Lumara Health IP Ltd.
6696083	2/24/2004	VITAMIN/NUTRIENT DOSAGE REGIMENTATION	Issued	United States of America	Lumara Health IP Ltd.
5554379	09/10/1996	LONG ACTING GI AND ESOPHAGEAL PROTECTANT	Issued	United States of America	Lumara Health IP Ltd.
5494678	02/27/1996	MULTI-VITAMIN AND MINERAL SUPPLEMENT FOR PREGNANT WOMEN	Issued	United States of America	Lumara Health IP Ltd.
5670163	09/23/1997	LONG ACTING GI AND ESPHAGEAL PROTECTANT	Issued	United States of America	Lumara Health IP Ltd.
5554380	09/10/1996	BIOADHESIVE PHARMACEUTICAL DELIVERY SYSTEM	Issued	United States of America	Lumara Health IP Ltd.
5858391	01/12/1999	LONG ACTING GI AND ESOPHAGEAL PROTECTANT	Issued	United States of America	Lumara Health IP Ltd.
6488956	12/03/2002	MULTI-VITAMIN AND MINERAL SUPPLEMENTS FOR WOMEN	Issued	United States of America	Lumara Health IP Ltd.
6899890	05/31/2005	BIOADHESIVE DRUG DELIVERY SYSTEM	Issued	United States of America	Lumara Health IP Ltd.
8057433	11/15/2011	DELIVERY SYSTEM	Issued	United States of America	Lumara Health IP Ltd.
7727972	06/01/2010	METHODS FOR DETERMINING ABSORPTION OF COBALAMIN OR ANALOGUES THEREOF	Issued	United States of America	Lumara Health IP Ltd.
12/971,900	12/17/2010	METHODS FOR REDUCING THE OCCURRENCE OF PRETERM DELIVERY AND OTHER PREGNANCY- RELATED CONDITIONS	Published	United States of America	Lumara Health IP Ltd.
13/554,243	7/20/2012	METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION	Published	United States of America	Lumara Health IP Ltd.
12/891,376	9/27/2010	METHODS OF ADMINISTERING COMPOSITIONS INCLUDING IRON	Published	United States of America	Lumara Health IP Ltd.
12/209864	09/12/2008	TRANSDERMAL, ALCOHOL-FREE,	Published	United States of America	Lumara Health IP Ltd.

13/555472	07/23/2012	PHARMACEUTICAL COMPOSITIONS	Published	United States of America	Lumara Health IP Ltd.
13/557527	07/25/2012	PHARMACEUTICAL DELIVERY SYSTEM COMPOSITION FOR TOPICAL TREATMENT OF MIXED	Published	United States of America	Lumara Health IP Ltd.
13/733213	01/03/2013	ENDOMETRIOSIS TREATMENT	Published	United States of America	Lumara Health IP Ltd.

CBR SYSTEMS, INC.

PATENTS AND PATENT APPLICATIONS

Patent No.	Date	Title	Status	Country	Patent Holder
5993387	11/30/99	Computer-based mixed-use registry of placental and umbilical cord stem cells	Granted	United States of America	CBR Systems, Inc.

SCHEDULE C

Copyrights

See attached.

LUMARA HEALTH INC.

COPYRIGHTS AND COPYRIGHT APPLICATIONS

<u>Description</u>	<u>Issued Date</u>	<u>Registration No.</u>	<u>Country</u>
Guafinex-Rx DM ¹	2/12/1997	TXu000811031	United States of America

¹ In accordance with Section 6.17 of the Credit Agreement, property title to be corrected with the US Copyright Office post closing.